ATHA vs. MNOV, CRVO, PYRGF, UNCY, IZTC, QNTM, IFRX, APLT, ABVC, and ICCC
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include MediciNova (MNOV), CervoMed (CRVO), PyroGenesis Canada (PYRGF), Unicycive Therapeutics (UNCY), Invizyne Technologies (IZTC), Quantum Biopharma (QNTM), InflaRx (IFRX), Applied Therapeutics (APLT), ABVC BioPharma (ABVC), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs. Its Competitors
Athira Pharma (NASDAQ:ATHA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.
Athira Pharma has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
MediciNova has higher revenue and earnings than Athira Pharma. MediciNova is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
MediciNova's return on equity of -20.77% beat Athira Pharma's return on equity.
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 22.1% of Athira Pharma shares are held by insiders. Comparatively, 13.6% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, MediciNova had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.87 beat MediciNova's score of 0.94 indicating that Athira Pharma is being referred to more favorably in the media.
Athira Pharma currently has a consensus price target of $11.25, suggesting a potential upside of 2,657.35%. MediciNova has a consensus price target of $7.00, suggesting a potential upside of 469.11%. Given Athira Pharma's higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than MediciNova.
Summary
MediciNova beats Athira Pharma on 9 of the 15 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 7/18/2025 by MarketBeat.com Staff
